Presented by
IVBM Event Coverage
Resource Demands Challenge Community Oncology: Christos Vaklavas, MD
In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.
CAR T Access Challenged by Geography, Cost, and Treatment Delays
Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.
Access, Logistics Shape Multiple Myeloma Immunotherapy Decisions
Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.
Distance, Telehealth Access Complicate Cancer Care in the Mountain West
Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.
Patient, Disease Factors Shape Multiple Myeloma Treatment Decisions
Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.
Addressing Biomarker Testing Gaps in NSCLC: Shiven B. Patel, MD, MBA
Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.
Adaptive Trials Cut Time to Effective Breast Cancer Therapies: Laura Esserman, MD, MBA
Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.
ADCs and Oral SERDs Reshape Breast Cancer Pharmacy Role: Tiffany Meng, PharmD
ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.
Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD
Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.
Communication Is Key to Successful Cell Therapy Trials: Bridget Keenan, MD, PhD
Bridget Keenan, MD, PhD, of UCSF, stresses close communication across clinical, industry, and lab teams to run safe CAR T-cell trials.
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.
Expanding Access to CAR T, Bispecific Therapies Requires System Changes: Peter Forsberg, MD
Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.
Multidisciplinary Geriatric Oncology Improves Breast Cancer Care: Enrique Soto Perez de Celis, MD
Multidisciplinary geriatric oncology helps personalize breast cancer care and preserve quality of life for older adults.
Multiple Myeloma Care Now Hinges on Delivery, Not Efficacy: Hans Lee, MD
Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.
Streamlining Clinical Trial Enrollment With Health Technology: Anosheh Afghahi, MD
Anosheh Afghahi, MD, explains how integrated health technologies can improve clinical trial matching, efficiency, and equity.
Oncology Innovation Meets the Realities of Access, Cost, and Coordination
Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.
Older Adult Priorities Should Shape Breast Cancer Trial Design: Enrique Soto Perez de Celis, MD, PhD
Enrique Soto Perez de Celis, MD, PhD, discusses designing breast cancer trials around outcomes older adults value, including independence and quality of life.
Breast Cancer De-Escalation Now Rests on Molecular Profiling: Denise Yardley, MD
Denise Yardley, MD, on OPTIMA, Prosigna proliferation scoring, and telling patients an endocrine strategy fits how their tumor behaves.
Precision Therapies Are Advancing Fast, and Care Delivery Has to Catch Up
Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.
Specialty Pharmacy Continuity is Lost When PBMs Steer Patients: Brooke Looney, PharmD, CSP
Integrated specialty pharmacies have EHR access, faster prior authorizations, and built-in monitoring, Brooke Looney, PharmD, CSP, highlighted.
Improving Clinical Trial Enrollment Through Biomarker Testing: Anosheh Afghahi, MD
Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve enrollment.
Nectin-4, Variant Histology, and What Comes Next: Benjamin Garmezy, MD
Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.
Multidisciplinary Teams Improve Biomarker Testing and Lung Cancer Care: Urs Weber, MD
Urs Weber, MD, explains how multidisciplinary teams streamline biomarker testing and improve treatment planning in thoracic oncology.
The Biomarker Gap in Triple-Negative Breast Cancer: Justin Balko, PharmD, PhD
Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.
Adequate Biomarker Testing Remains Key Gap in Community Oncology Care: Urs Weber, MD
Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.
Oncology Workflows Shift as Drug Delivery, Monitoring Change: Angie Maynard, PharmD, MS, BCOP
Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.
Expanding the Role of PCSK9, SGLT2 Inhibitors in Cardiovascular Prevention: Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.
Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA
Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.
